Table 2.

Cox proportional hazard analysis (95% CI) for persistence of TNF inhibitor

	HR naive (n = 1,468)	HR continuing (n = 733)	HR overall (n = 2,201)
Gender (0: male/1: female)	0.942 (0.780-1.138)	0.937 (0.723-1.215)	0.943 (0.810-1.099)
Age	0.999 (0.994-1.005)	0.990 (0.983-0.997)*	0.996 (0.992-1.000)
Medication (reference category: Infliximab)
Etanercept	0.960 (0.788-1.170)	1.084 (0.850-1.381)	1.001 (0.865-1.175)
Adalimumab	0.956 (0.786-1.163)	1.023 (0.790-1.323)	0.983 (0.842-1.148)
Charlson Comorbidities Index	1.018 (0.968-1.071)	1.055 (0.974-1.143)	1.030 (0.987-1.075)
Naive	-	-	1.296 (1.164-1.443)**

*p ≤ 0.005.

**p = 0.000.